Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 7/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28679876 | 0.85 | CA1 (0.37) | KDM4EKMT2AACHE | |
| SCHEMBL27033654 | 0.84 | HTR2C (0.39) | MTNR1A | |
| SCHEMBL30711613 | 0.84 | HTR2C (0.39) | MTNR1A | |
| SCHEMBL10581361 | 0.81 | PIN1 (0.46) | KMT2AIDO1PIN1 | |
| SCHEMBL12256766 | 0.78 | KMT2A (0.42) | PDE10AKDM4EMTNR1AKMT2ATRPV1 | |
| SCHEMBL14059338 | 0.77 | KMT2A (0.39) | MTNR1AKMT2ANQO2MTNR1BACHE | |
| SCHEMBL10335453 | 0.75 | ADRA2A (0.53) | KDM4EDRD2DRD1 | |
| SCHEMBL25598732 | 0.73 | MEN1 (0.45) | KMT2A | |
| SCHEMBL15630785 | 0.72 | CA1 (0.39) | KDM4EKMT2AACHE | |
| SCHEMBL12256765 | 0.72 | DRD2 (0.40) | TRPV1DRD2DRD1IDO1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | PDE10A 319/4885KDM4E 3906/4885MTNR1A 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.